Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Peripheral Nervous System Neoplasms

ClinicalTrials.gov lists 363 trials for Peripheral Nervous System Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 59.

MeSH D010524 Neoplasms Neoplasm C04 C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 87 Phase 1/2 Phase 1/2 29 Phase 2 Phase 2 103 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 18 Phase 4 Phase 4 3 Not applicable Not applicable 55 Observational Observational 62 Phase 1 Phase 1 87 Phase 1/2 Phase 1/2 29 Phase 2 Phase 2 103 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 18 Phase 4 Phase 4 3 Not applicable Not applicable 55 Observational Observational 62

Trials per phase (log scale)

1 more section with rows

4 of the 363 trials are tagged with Peripheral Nervous System Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Peripheral Nervous System Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Peripheral Nervous System Neoplasms trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 19

1992: 1 trials (Observational 1) 1993: 1 trials (Phase 2 1) 1994: 2 trials (Phase 2 1, Phase 1 1) 1995: 1 trials (Phase 3 1) 1996: 1 trials (Phase 3 1) 1997: 4 trials (Phase 3 2, Phase 1 2) 1998: 5 trials (Phase 3 1, Phase 2 3, Phase 1 1) 1999: 6 trials (Phase 2 3, Phase 1 3) 2000: 9 trials (Not applicable 1, Phase 2 2, Phase 1/2 2, Phase 1 4) 2001: 7 trials (Observational 1, Phase 2 3, Phase 1 3) 2002: 10 trials (Observational 1, Not applicable 1, Phase 2 2, Phase 1 6) 2003: 7 trials (Phase 3 1, Phase 2 4, Phase 1 2) 2004: 9 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 2, Phase 1 3) 2005: 15 trials (Observational 3, Not applicable 1, Phase 2 3, Phase 1 8) 2006: 13 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 5, Phase 1 4) 2007: 11 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 3, Phase 1 3) 2008: 15 trials (Observational 5, Not applicable 1, Phase 2 3, Phase 1/2 1, Phase 1 5) 2009: 8 trials (Phase 2 2, Phase 1/2 1, Phase 1 5) 2010: 13 trials (Observational 3, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 6) 2011: 12 trials (Not applicable 2, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1/2 2, Phase 1 3) 2012: 9 trials (Observational 1, Phase 2 7, Phase 1/2 1) 2013: 9 trials (Observational 1, Not applicable 3, Phase 1/2 3, Phase 1 2) 2014: 11 trials (Not applicable 4, Phase 2/3 1, Phase 2 5, Phase 1 1) 2015: 16 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 1, Phase 2 5, Phase 1/2 3, Phase 1 3) 2016: 8 trials (Observational 2, Not applicable 1, Phase 2 5) 2017: 19 trials (Observational 6, Not applicable 3, Phase 2 7, Phase 1 3) 2018: 17 trials (Observational 7, Not applicable 4, Phase 2 5, Phase 1/2 1) 2019: 18 trials (Observational 5, Not applicable 6, Phase 4 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2020: 12 trials (Observational 1, Not applicable 3, Phase 2 2, Phase 1 6) 2021: 19 trials (Observational 5, Not applicable 3, Phase 3 1, Phase 2 6, Phase 1/2 2, Phase 1 2) 2022: 12 trials (Observational 2, Not applicable 6, Phase 2 1, Phase 1/2 1, Phase 1 2) 2023: 11 trials (Observational 4, Not applicable 1, Phase 3 1, Phase 2 2, Phase 1/2 2, Phase 1 1) 2024: 12 trials (Observational 4, Not applicable 3, Phase 2 4, Phase 1/2 1) 2025: 16 trials (Observational 1, Not applicable 4, Phase 3 1, Phase 2 4, Phase 1/2 3, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 18
2025 16
2024 12
2023 11
2022 12
2021 19
2020 12
2019 18
2018 17
2017 19

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 22 trials starting in 2026 and about 17 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 44 trials still running at the 2026-10-09 snapshot; registered median of 47 months across 213 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Peripheral Nervous System Neoplasms trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 87
Phase 1/2 29
Phase 2 103
Phase 2/3 3
Phase 3 18
Phase 4 3
Not applicable 55
Observational 62
Expanded access 3

How many Peripheral Nervous System Neoplasms trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 8
Recruiting 54
Enrolling by invitation 7
Active, not recruiting 27
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Peripheral Nervous System Neoplasms trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 59
Children's Oncology Group 14
European Organisation for Research and Treatment of Cancer - EORTC 13
Pediatric Brain Tumor Consortium 8
AstraZeneca 7

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Peripheral Nervous System Neoplasms? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Selumetinib 17
EVEROLIMUS 7
Imatinib 6
Luvometinib 5

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Doxorubicine 20
Ifosfamid 15
SOC: Temozolomide 14
Radiation Therapy 13
or carboplatin 12

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Peripheral Nervous System Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Vomiting 59 15
Dyspnea 49 9
Pleural effusion 46 9
Fever 40 13
Febrile neutropenia 39 6

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Peripheral Nervous System Neoplasms? (40)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Diagnostic Criteria for Symptomatic Neuroma. Annals of plastic surgery 2019 Yes
Peripheral Interventions for Painful Stump Neuromas of the Lower Limb: A Systematic Review. The Clinical journal of pain 2018 Yes
Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. The bone & joint journal 2016 Yes
Traumatic neuroma of the superficial peroneal nerve in a patient: a case report and review of the literature. World journal of surgical oncology 2016 Yes
Imaging of the cerebello-pontine angle. Practical neurology 2014 Yes

Showing 5 of 40 publications.

Start your 14-day trial Email me all 40 publications as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages